Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

NCT03126916 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03126916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03126916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Recruiting
Start date
May 14, 2018
Completion date
September 30, 2030
Enrollment
750 (estimated)
Sites
164

Conditions

As the registry lists them; a condition with its own page is linked.

ganglioneuroblastoma, ganglioneuroblastoma, nodular, neuroblastoma